The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | DART trial: dasatinib and quercetin in patients with R/R multiple myeloma receiving CAR-T therapy
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the Phase II DART trial (NCT06940297) evaluating the senolytic agents dasatinib and quercetin alongside ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma. She highlights the rationale for targeting senescent-like myeloma cells and notes that the six-patient safety run-in showed no severe adverse effects or apparent impact on CAR T-cell expansion, with encouraging early rates of dual MRD and PET negativity. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
